Personal information

No personal information available

Activities

Collapse all

Works (17)

Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma

Bone Marrow Transplantation
2025-02-01 | Journal article
DOI: 10.1038/s41409-025-02519-z
Contributors: Magdalena Corona; Andrew Ip; Samantha Brown; Alejandro Luna; Hazim Khatib; Jessica R. Flynn; Sean M. Devlin; Ivan Landego; Giulio Cassanello; Kai Rejeski et al.
Source: check_circle
Crossref

Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study

Hemato
2025-01 | Journal article | Author
DOI: 10.3390/hemato6010003
Contributors: Aishwarya Sridhar; Thomas Gunning; Alexandra Hampson; Xiaopei ZHANG; Jaeil Ahn; Brittany Sinclaire; Brittany Lukasik; Christina Cho; Michele L. Donato; Sukhdeep Kaur et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies

Cancers
2025-01-17 | Journal article
DOI: 10.3390/cancers17020282
Contributors: Ayrton Bangolo; Behzad Amoozgar; Charlene Mansour; Lili Zhang; Sarvarinder Gill; Andrew Ip; Christina Cho
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors

Heliyon
2023-05 | Journal article
DOI: 10.1016/j.heliyon.2023.e16261
Contributors: Maher Albitar; Hong Zhang; Ahmad Charifa; Andrew Ip; Wanlong Ma; James McCloskey; Michele Donato; David Siegel; Stanley Waintraub; Martin Gutierrez et al.
Source: check_circle
Crossref

Differential Diagnosis of Hematologic and Solid Tumors Using Targeted Transcriptome and Artificial Intelligence

The American Journal of Pathology
2023-01 | Journal article
DOI: 10.1016/j.ajpath.2022.09.006
Contributors: Hong Zhang; Muhammad A. Qureshi; Mohsin Wahid; Ahmad Charifa; Aamir Ehsan; Andrew Ip; Ivan De Dios; Wanlong Ma; Ipsa Sharma; James McCloskey et al.
Source: check_circle
Crossref

Anti-spike antibody response to the COVID vaccine in lymphoma patients

PLOS ONE
2022-12-01 | Journal article
DOI: 10.1371/journal.pone.0266584
Contributors: Alexandra Della Pia; Victor C. Huber; Gee Youn (Geeny) Kim; Andrew Ip; Jaeil Ahn; Yanzhi Liu; Simone Kats; Michael Koropsak; Brittany Lukasik; Anamta Contractor et al.
Source: check_circle
Crossref

Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era

Cancers
2022-08 | Journal article | Author
DOI: 10.3390/cancers14174252
Contributors: Alexandra Della Pia; Charles Zhao; Parul Jandir; Amolika Gupta; Mark Batistick; Geeny Lee; Yi Xia; Jaeil Ahn; Gabriella Magarelli; Brittany Lukasik et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Production of anti-spike antibodies in response to COVID vaccine in lymphoma patients

2022-03-24 | Preprint
DOI: 10.1101/2022.03.24.22272883
Contributors: Alexandra Della Pia; Gee Youn (Geeny) Kim; Andrew Ip; Jaeil Ahn; Yanzhi Liu; Simone Kats; Michael Koropsak; Brittany Lukasik; Anamta Contractor; Krushna Amin et al.
Source: check_circle
Crossref

Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study

BMC Infectious Diseases
2021-12 | Journal article
DOI: 10.1186/s12879-021-05773-w
Contributors: Andrew Ip; Jaeil Ahn; Yizhao Zhou; Andre H. Goy; Eric Hansen; Andrew L. Pecora; Brittany A. Sinclaire; Urszula Bednarz; Michael Marafelias; Ihor S. Sawczuk et al.
Source: check_circle
Crossref

Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19

PLOS ONE
2021-07-30 | Journal article
DOI: 10.1371/journal.pone.0255228
Contributors: Donald A. Berry; Pasquale Abete; Andrew Ip; Brett E. Lewis; Scott M. Berry; Nicholas S. Berry; Mary MrKulic; Virginia Gadalla; Burcu Sat; Kristen Wright et al.
Source: check_circle
Crossref

Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma

JCI Insight
2021-03-22 | Journal article
DOI: 10.1172/jci.insight.143196
Contributors: Michele L. Donato; Steven Park; Melissa Baker; Robert Korngold; Alison Morawski; Xue Geng; Ming Tan; Andrew Ip; Stuart Goldberg; Scott Rowley et al.
Source: check_circle
Crossref

Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study

2020-08-25 | Other
DOI: 10.1101/2020.08.20.20178772
Contributors: Andrew Ip; Jaeil Ahn; Yizhao Zhou; Andre H. Goy; Eric Hansen; Andrew L Pecora; Brittany A Sinclaire; Urszula Bednarz; Michael Marafelias; Shivam Mathura et al.
Source: check_circle
Crossref

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study

PLOS ONE
2020-08-13 | Journal article
DOI: 10.1371/journal.pone.0237693
Contributors: Andrew Ip; Chiara Lazzeri; Donald A. Berry; Eric Hansen; Andre H. Goy; Andrew L. Pecora; Brittany A. Sinclaire; Urszula Bednarz; Michael Marafelias; Scott M. Berry et al.
Source: check_circle
Crossref

Induction Therapy in Localized Pancreatic Cancer

Pancreas
2019-08 | Journal article
DOI: 10.1097/mpa.0000000000001353
Part of ISSN: 1536-4828
Part of ISSN: 0885-3177
Source: Self-asserted source
Andrew Ip

The association of physical activity before and after lymphoma diagnosis with survival outcomes

American Journal of Hematology
2018-12 | Journal article
DOI: 10.1002/ajh.25288
Part of ISSN: 0361-8609
Source: Self-asserted source
Andrew Ip

PI3K Inhibitors: Understanding Toxicity Mechanisms and Management

Oncology (Williston Park, N.Y.)
2017-11 | Journal article
Source: Self-asserted source
Andrew Ip

Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer

The Oncologist
2016-02 | Journal article
DOI: 10.1634/theoncologist.2015-0316
Part of ISSN: 1083-7159
Part of ISSN: 1549-490X
Source: Self-asserted source
Andrew Ip

Peer review (1 review for 1 publication/grant)

Review activity for Nature communications (1)
How many people are using ORCID?